Retroperitoneoscopic nephroureterectomy for renal pelvic tumors with a single iliac incision

• Published in: The Journal of urology Vol. 161; no. 2; p. 541
• Main Authors: Salomon, L, Hoznek, A, Cicco, A, Gasman, D, Chopin, D K, Abbou, C C
• Format: Journal Article
• Language: English
• Published: United States 01-02-1999
• Subjects: Aged; Female; Humans; Kidney Neoplasms - surgery; Kidney Pelvis - surgery; Laparoscopy - methods; Male; Middle Aged; Nephrectomy - methods; Retroperitoneal Space; Ureter - surgery; Urologic Surgical Procedures - methods
• ISSN: 0022-5347
• DOI: 10.1016/s0022-5347(01)61945-1

Retroperitoneal laparoscopy, by providing direct access to the retroperitoneal cavity, is a useful approach to urological surgery. We applied this technique to nephroureterectomy in patients with tumors of the renal pelvis.
Between January 1995 and March 1997 we performed 4 retroperitoneal laparoscopic nephroureterectomies in patients with tumors of the renal pelvis. The patients were placed in the lateral decubitus position. Five trocars were used. Balloon dilation was not contributory. Radical nephrectomy was performed and the kidney was left in the retroperitoneal space. Via an iliac incision ureterectomy with a bladder cuff was performed and the specimen was removed (kidney and ureter) en bloc via this incision without opening the urinary tract.
One right and 3 left nephroureterectomies were performed with an average operating time of 220 minutes (range 160 to 300). Average kidney size was 110 mm. (range 100 to 120). Average hospital stay was 5.7 days (range 5 to 7). Blood loss was minimal and postoperative analgesic requirements were moderate. Conversion to open surgery was never necessary. The morbidity rate was zero. The pathological stages were pT2 G2, pT3 G2, pT3G3 and pT3 G2-G3 N+. A local recurrence was observed in a patient with a pT3 G3 tumor.
Nephroureterectomy can be performed by retroperitoneal laparoscopy. The perioperative morbidity and hospital stay are reduced. Further followup is required to evaluate long-term results in terms of cancer outcome.